25 recruiting, 16 completed, 13 active not recruiting, 13 terminated. 77 Phase 1, 38 Phase 2.
Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-12-01 | 2026-11-03 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors 5 Azacytidine, Pembrolizumab, Nivolumab - Solid Tumor, Locally Advanced Solid Tumor | Phase 1 | Recruiting | Mohammed Milhem | 35 | 2026-02-11 | 2026-05-28 |
| Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma cemiplimab, Topical imiquimod - Cutaneous Basal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Instituto Oncológico Dr Rosell | 18 | 2025-10-22 | 2025-12-01 |
| A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC REGN5678, Cemiplimab - Prostate Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 60 | 2025-07-09 | 2026-08-14 |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2025-06-03 | 2026-10-05 |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors BHV-1530, Cemiplimab - Solid Tumor | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 140 | 2025-03-20 | 2026-07-09 |
| BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma Cemiplimab - Mycosis Fungoides | Phase 1 / Phase 2 | Withdrawn | AHS Cancer Control Alberta | 2024-12-01 | 2025-06-27 | |
| Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC Dupilumab, Cemiplimab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 21 | 2024-10-09 | 2026-07-21 |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body REGN10597, Cemiplimab - Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 240 | 2024-09-23 | 2026-04-28 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2024-08-28 | 2026-06-26 |
| Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) S095018, S095024, S095029 - Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Active not recruiting | Servier Bio-Innovation LLC | 102 | 2024-08-07 | 2026-11-12 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers 27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2024-08-06 | 2026-02-03 |
| Trial of INI-4001 in Patients With Advanced Solid Tumours INI-4001, Nivolumab, Pembrolizumab - Advanced Solid Tumor | Phase 1 | Completed | Inimmune Corporation | 10 | 2024-07-01 | 2026-10-16 |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors BHV-1510, Cemiplimab - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Biohaven Therapeutics Ltd. | 500 | 2024-04-22 | 2026-09-28 |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors tolododekin alfa, Cemiplimab - Advanced Solid Tumor, Cutaneous Tumor | Phase 1 | Recruiting | Ankyra Therapeutics, Inc | 97 | 2024-01-19 | 2026-03-06 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
Showing 20 of 77. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Neoplasm Metastasis (12) · Neoplasms (11) · Melanoma (10) · Ovarian Neoplasms (7) · Prostatic Neoplasms (7) · Head and Neck Neoplasms (6) · Recurrence (6) · Squamous Cell Carcinoma of Head and Neck (6) · Breast Neoplasms (5) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Skin Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Endometrial Neoplasms (3)
Regeneron Pharmaceuticals (22) · Sanofi (6) · M.D. Anderson Cancer Center (4) · BioNTech SE (2) · Biohaven Therapeutics Ltd. (2) · Dana-Farber Cancer Institute (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · OncoResponse, Inc. (2) · AHS Cancer Control Alberta (1) · Ankyra Therapeutics, Inc (1) · Bolt Biotherapeutics, Inc. (1) · EMD Serono Research & Development Institute, Inc. (1)
United States (63) · Spain (19) · Australia (14) · France (13) · Netherlands (10) · South Korea (10) · United Kingdom (10) · Italy (8) · Belgium (7) · Germany (7) · Canada (6) · Brazil (4) · Hungary (4) · Israel (4) · Taiwan (4)
Adam Dicker, MD (1) · Aixa E Soyano Muller, MD (1) · Alison O'Neill, MD (1) · Bilal Siddiqui, MD (1) · Christine Parseghian, MD (1) · Cynthia Gay, MD (1) · David A Reardon, MD (1) · Debika Bhattacharya, MD (1) · Douglas McNeel, MD (1)
PMID 35175355, PMID 27879972, PMID 29863979, PMID 32554615, PMID 33146741, PMID 33224628, PMID 33477979, PMID 33831732, PMID 33929394, PMID 33942954, PMID 35058326, PMID 36821617, PMID 36898933, PMID 37315579, PMID 38252908, PMID 38449916, PMID 38898592, PMID 38900987, PMID 39422598, PMID 39652449, PMID 40152791, PMID 40713179, PMID 40852760, PMID 41022754, PMID 41781018, PMID 42173654
2017 (3), 2018 (3), 2023 (3), 2025 (3), 2015 (2), 2016 (2), 2019 (2), P50CA186781 (2), R01CA262613 (2), P30CA014089 (1), P30CA068485 (1), P30CA138292 (1), P50CA269011 (1), UM1CA186690 (1), UM1CA186691 (1)